Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Travere Therapeutics Inc

Healthcare US TVTX

45.2USD
2.24(5.21%)

Last update at 2026-06-03T20:00:00Z

Day Range

43.0945.57
LowHigh

52 Week Range

5.1219.54
LowHigh

Fundamentals

  • Previous Close 42.96
  • Market Cap468.95M
  • Volume1769666
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-376.56301M
  • Revenue TTM155.72M
  • Revenue Per Share TTM2.04
  • Gross Profit TTM -31.35400M
  • Diluted EPS TTM-5.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -278.16900M -179.68200M -188.79000M -146.44800M -101.86700M
Minority interest - - - - -
Net income -278.48200M -180.09100M -169.43100M -146.42700M -102.67800M
Selling general administrative 220.21M 149.88M 135.80M 128.95M 103.65M
Selling and marketing expenses - - - - -
Gross profit 204.43M 220.71M 192.19M 170.10M 158.72M
Reconciled depreciation 33.08M 26.62M 24.58M 20.41M 18.67M
Ebit -251.56000M -139.50500M -75.37700M -99.81000M -82.33500M
Ebitda -244.31000M -137.28100M -68.95400M -69.66100M -63.66700M
Depreciation and amortization 7.25M 2.22M 6.42M 30.15M 18.67M
Non operating income net other -0.32800M 2.22M 6.42M - -
Operating income -251.56000M -139.50500M -75.37700M -99.81000M -80.04000M
Other operating expenses 463.58M 367.00M 273.70M 275.15M 232.94M
Interest expense 11.28M 20.14M 19.05M 18.83M 9.81M
Tax provision 0.31M 0.41M -19.35900M -0.02100M 0.81M
Interest income 6.28M 1.99M 5.00M 10.05M 5.50M
Net interest income -4.99900M -18.14800M -14.04700M -8.77300M -4.31100M
Extraordinary items - - - - -
Non recurring - - 97.13M - -
Other items - - - - -
Income tax expense 0.31M 0.41M -19.35900M -0.02100M 0.81M
Total revenue 212.02M 227.49M 198.32M 175.34M 164.25M
Total operating expenses 455.99M 360.21M 267.57M 269.91M 227.41M
Cost of revenue 7.59M 6.78M 6.13M 5.23M 5.53M
Total other income expense net -26.60900M -40.17700M -113.41300M -46.63800M -28.86400M
Discontinued operations - - - - -
Net income from continuing ops -278.48200M -180.09100M -169.43100M -146.42700M -102.67800M
Net income applicable to common shares -278.48200M -180.09100M -169.43100M -146.42700M -102.67800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 788.91M 672.59M 776.63M 607.44M 604.80M
Intangible assets 103.69M 145.04M 148.44M 153.19M 157.20M
Earning assets - - - - -
Other current assets 19.34M 12.62M 6.47M 8.14M 6.41M
Total liab 588.10M 629.73M 474.52M 396.23M 383.60M
Total stockholder equity 200.81M 42.85M 302.11M 211.21M 221.20M
Deferred long term liab - - - - -
Other current liab 124.23M 108.46M 88.77M 80.53M 68.83M
Common stock 0.00700M 0.00600M 0.00600M 0.00500M 0.00400M
Capital stock 0.00700M 0.00600M 0.00600M 0.00500M 0.00400M
Retained earnings -1125.62200M -1014.22300M -765.96600M -585.87500M -416.44400M
Other liab - 84.52M 92.36M 59.89M 83.29M
Good will 0.80M 0.90M 0.94M 0.94M 0.94M
Other assets - 0.04M 11.07M 7.81M 14.71M
Cash 58.18M 61.69M 165.75M 84.77M 62.44M
Cash and equivalents - - - - -
Total current liabilities 177.91M 142.16M 124.09M 92.66M 95.45M
Current deferred revenue 7.10M 11.98M 16.27M - -
Net debt 346.61M 345.80M 96.23M 130.57M 142.43M
Short term debt 4.91M 4.43M 3.91M 492.16M -
Short long term debt - - - - -
Short long term debt total 404.78M 407.49M 261.99M 215.34M 204.86M
Other stockholder equity 1327.88M 1059.97M 1068.63M 797.99M 636.91M
Property plant equipment - 9.05M 11.11M 35.09M 2.89M
Total current assets 616.77M 486.44M 582.83M 410.41M 429.06M
Long term investments - - - - 0.00000M
Net tangible assets - -102.18700M 153.68M 57.09M 63.06M
Short term investments 508.68M 388.56M 387.13M 276.82M 336.09M
Net receivables 21.18M 16.65M 16.16M 33.07M 18.05M
Long term debt 377.26M 375.55M 226.58M 215.34M 204.86M
Inventory 9.41M 6.92M 7.31M 7.61M 6.08M
Accounts payable 41.67M 17.29M 15.14M 12.13M 26.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.45600M -2.90700M -0.56200M -0.90200M 0.73M
Additional paid in capital - - - - -
Common stock total equity - 0.00600M 0.00600M 0.00500M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - -1014.22300M -765.96600M -585.87500M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 42.11M 11.06M 11.07M 33.49M 14.71M
Deferred long term asset charges - - - - -
Non current assets total 172.14M 186.15M 193.81M 197.03M 175.74M
Capital lease obligations 27.52M 31.94M 35.41M - -
Long term debt total - - - 215.34M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -3.39600M -113.47200M 58.52M 35.43M -183.59000M
Change to liabilities 22.84M 22.32M -6.03600M 9.26M -2.70800M
Total cashflows from investing activities -32.55300M -137.62300M -61.32700M 19.86M -203.29100M
Net borrowings 95.04M 104.93M 104.93M 104.93M 235.80M
Total cash from financing activities 117.57M 231.68M 127.71M -2.07700M 231.86M
Change to operating activities 14.65M 23.68M -1.49400M -0.04400M 14.82M
Net income -278.48200M -180.09100M -169.43100M -146.42700M -102.67800M
Change in cash -104.06500M 80.98M 22.34M -40.43700M 3.48M
Begin period cash flow 165.75M 84.77M 62.44M 102.87M 99.39M
End period cash flow 61.69M 165.75M 84.77M 62.44M 102.87M
Total cash from operating activities -186.29100M -14.79200M -42.74300M -58.21400M -24.95800M
Issuance of capital stock 19.55M 224.93M 131.52M - -
Depreciation 33.08M 26.62M 24.58M 20.41M 18.67M
Other cashflows from investing activities -28.96600M -19.05000M -113.07800M -0.60000M -
Dividends paid - - - - -
Change to inventory -2.06400M -1.81500M -5.06700M -1.95800M -2.77300M
Change to account receivables -0.68200M -0.05900M 2.30M -5.18400M 0.15M
Sale purchase of stock 27.11M 2.11M 2.05M - -
Other cashflows from financing activities 309.35M 4.64M -5.85300M -2.07700M 272.07M
Change to netincome 41.58M 23.19M 117.67M 55.28M 45.04M
Capital expenditures 28.56M 24.15M 119.84M 15.56M 19.70M
Change receivables -0.68200M -0.05900M 2.30M - -
Cash flows other operating -4.18900M 81.80M -12.54800M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -101.27100M 79.27M 23.64M - -
Change in working capital 0.90M 79.98M -26.04200M 2.68M 11.07M
Stock based compensation 39.18M 30.77M 23.61M 21.11M 19.77M
Other non cash items 19.03M 23.82M 102.54M 2.73M 7.86M
Free cash flow -214.84800M -38.94300M -162.58800M -73.77900M -44.65900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TVTX
Travere Therapeutics Inc		 2.24 5.21% 45.20 - - 3.34 2.41 2.22 -0.9893
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics Inc

3611 Valley Centre Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Eric M. Dube Ph.D. Pres, CEO & Director 1973
Ms. Elizabeth E. Reed Sr. VP, Gen. Counsel & Corp. Sec. 1971
Dr. William E. Rote Ph.D. Sr. VP of R&D 1963
Dr. Noah L. Rosenberg M.D. Exec. Advisor 1967
Mr. Christopher Cline C.F.A., CFA Chief Financial Officer 1984
Ms. Sandra Calvin VP, Corp. Controller & Principal Accounting Officer 1965
Ms. Charlotte Smith Sr. VP of Public Affairs NA
Mr. Casey Logan Sr. VP of Corp. & Bus. Devel. NA
Ms. Angela Giannantonio Sr. VP of HR NA
Mr. Peter Heerma Chief Commercial Officer 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions